Finasteride News and Research

RSS
Finasteride is a synthetic antiandrogen which acts by inhibiting type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). It is used as a treatment in benign prostatic hyperplasia (BPH) in low doses, and prostate cancer in higher doses. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.
Gene expression changes in prostate tissue surrounding cancer lesions may allow prostate cancer diagnosis

Gene expression changes in prostate tissue surrounding cancer lesions may allow prostate cancer diagnosis

New study: Men who consume hair loss drug may report sexual dysfunction

New study: Men who consume hair loss drug may report sexual dysfunction

5a-reductase inhibitors for male health problems can affect sexual health

5a-reductase inhibitors for male health problems can affect sexual health

Variation in PSA levels does not predict prostate cancer, may lead to unnecessary biopsies

Variation in PSA levels does not predict prostate cancer, may lead to unnecessary biopsies

Early balding linked to prostate cancer: Study

Early balding linked to prostate cancer: Study

Men going bald at young age more likely to develop prostate cancer in later life

Men going bald at young age more likely to develop prostate cancer in later life

BPH, hair loss prevention drugs may produce adverse side effects in men

BPH, hair loss prevention drugs may produce adverse side effects in men

FDA panel rejects expansion of drug label

FDA panel rejects expansion of drug label

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

Affordable Care Act that mandates free preventative services goes into effect in September

Affordable Care Act that mandates free preventative services goes into effect in September

Study shows physicians reluctant to use finasteride for prostate cancer

Study shows physicians reluctant to use finasteride for prostate cancer

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

DermaGenoma announces availability of PsoriasisDX Genetic Test as CE Marked product for PsA

DermaGenoma announces availability of PsoriasisDX Genetic Test as CE Marked product for PsA

Top treatments and tests for hair loss

Top treatments and tests for hair loss

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

DermaGenoma releases CelluliteDX Genetic Test for women

DermaGenoma releases CelluliteDX Genetic Test for women

Genetic dermatology tests merge with DermaGenoma

Genetic dermatology tests merge with DermaGenoma

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

Dutasteride reduces risk of prostate cancer

Dutasteride reduces risk of prostate cancer

Study indicates Finasteride therapy may benefit women suffering from hair loss

Study indicates Finasteride therapy may benefit women suffering from hair loss